Acadia Pharmaceuticals, Valeant Pharmaceuticals deal

Acadia regained rights to pimavanserin in the U.S. and Canada after it and Valeant Pharmaceuticals jointly terminated a 2009 deal. Valeant gained rights to pimavanserin through its merger with Biovail Corp. this year, but decided that the program was not consistent with its strategic focus following the merger, according to Acadia. Acadia will receive $8.8 million in cash from Valeant to transition the program and cover costs of ongoing trials. ...